The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Pharmaceutical Firms and the Transition to Biotechnology: A Study in Strategic Innovation
Abstract
During the twentieth century, the pharmaceutical industry experienced a series of dramatic changes as developments in science and technology generated new opportunities for innovation. Each of these transitions forced existing firms to develop new capabilities. The authors examine the most recent such transition, the shift to molecular genetics and recombinant DNA technology (1970 to the present), and explain how and why this transformation differed from the previous ones in pharmaceuticals. Small biotech startups played an important role in this transition, and the large pharmaceutical firms that began to enter the field had to develop new strategies for innovation. Two major strategies were adopted by the early movers, all of which created various kinds of alliances with the small biotech businesses. By the mid-1990s, the leading pharmaceutical manufacturers had established significant capabilities in the new field, but they were continuing to work with specialized biotechs in order to innovate across a broad range of therapeutic categories.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · doi:10.1093/oso/9780195076165.001.0001 · Cited by 3,069
Cited by
Building Dynamic Capabilities: Innovation Driven by Individual-, Firm-, and Network-Level Effects
Rothaermel, F. T., & Hess, A. M. (2007) · Organization Science · doi:10.1287/orsc.1070.0291 · Cited by 979
Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry
Acemoglu, D., & Linn, J. (2004) · The Quarterly Journal of Economics · doi:10.1162/0033553041502144 · Cited by 967
A Comparison of U.S. and European University-Industry Relations in the Life Sciences
Owen-Smith, J., Riccaboni, M., Pammolli, F., & Powell, W. W. (2002) · Management Science · doi:10.1287/mnsc.48.1.24.14275 · Cited by 516
Hess, A. M., & Rothaermel, F. T. (2011) · Strategic Management Journal · doi:10.1002/smj.916 · Cited by 492
Attentional Triangulation: Learning from Unexpected Rare Crises
Rerup, C. (2009) · Organization Science · doi:10.1287/orsc.1090.0467 · Cited by 460
Vassolo, R. S., Anand, J., & Folta, T. B. (2004) · Strategic Management Journal · doi:10.1002/smj.414 · Cited by 435
Plus ca change: Industrial R&D in the "third industrial revolution"
Mowery, D. C. (2008) · Industrial and Corporate Change · doi:10.1093/icc/dtn049 · Cited by 350
Paruchuri, S., Nerkar, A., & Hambrick, D. C. (2006) · Organization Science · doi:10.1287/orsc.1060.0207 · Cited by 347
The dynamics of technological innovation: the case of the pharmaceutical industry
Achilladelis, B., & Antonakis, N. (2001) · Research Policy · doi:10.1016/s0048-7333(00)00093-7 · Cited by 334
Grigoriou, K., & Rothaermel, F. T. (2017) · Strategic Management Journal · doi:10.1002/smj.2489 · Cited by 314
Inter-firm R&D partnering in pharmaceutical biotechnology since 1975: Trends, patterns, and networks
Roijakkers, N., & Hagedoorn, J. (2006) · Research Policy · doi:10.1016/j.respol.2006.01.006 · Cited by 311
Role of Recombinant DNA Technology to Improve Life
Khan, S., Ullah, M. W., Siddique, R., Nabi, G., Manan, S., Yousaf, M., & Hou, H. (2016) · International Journal of Genomics · doi:10.1155/2016/2405954 · Cited by 279
Does firm innovativeness enable effective responses to supply chain disruptions? An empirical study
Golgeci, I., & Y. Ponomarov, S. (2013) · Supply Chain Management: An International Journal · doi:10.1108/scm-10-2012-0331 · Cited by 272
Malerba, F. (2002) · Industrial and Corporate Change · doi:10.1093/icc/11.4.667 · Cited by 265
Metadata
- Authors
- Galambos, L., & Sturchio, J. L.
- Venue
- Business History Review
- Publisher
- Cambridge University Press (CUP)
- Published
- 1998
- Volume
- 72
- Issue
- 2
- Pages
- 250-278
- ISSN
- 0007-6805 (ISSN-L)
- 2044-768X
- OpenAlex
- W2140169779
- Cited by
- 203
- References
- 1
- FWCI
- 2.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.